{"id":31783,"date":"2025-03-31T11:30:00","date_gmt":"2025-03-31T03:30:00","guid":{"rendered":"https:\/\/flcube.com\/?p=31783"},"modified":"2025-04-15T11:39:12","modified_gmt":"2025-04-15T03:39:12","slug":"apollomics-partners-with-launxp-for-vebreltinib-in-asian-nsclc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31783","title":{"rendered":"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment"},"content":{"rendered":"\n

Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.<\/p>\n\n\n\n

Financial Terms and Responsibilities<\/strong>
Under the agreement, Apollomics will receive a $10 million upfront payment and is eligible for up to $50 million in clinical development and regulatory milestone payments, along with royalties on future net sales. LaunXP will lead the development of the vebreltinib-EGFR inhibitor combination therapy in the region.<\/p>\n\n\n\n

Vebreltinib: Mechanism and Approval Status<\/strong>
Vebreltinib is a potent, orally bioavailable, and highly selective c-MET inhibitor that targets the HGF\/c-MET pathway, which plays a critical role in tumor growth, proliferation, and resistance to targeted therapies like osimertinib. The drug has received conditional approval from China\u2019s National Medical Products Administration (NMPA) and is under global clinical investigation, though it remains unapproved in other regions.<\/p>\n\n\n\n

Clinical Efficacy and Data Highlights<\/strong>
Vebreltinib has demonstrated significant efficacy in both treatment-na\u00efve and previously treated NSCLC patients, with objective response rates (ORR) of 66.7% and 61.1%, respectively. The median duration of response (DOR) and progression-free survival (PFS) also showed promising results, with DOR of 17.3 months and PFS of 13.8 months in treatment-na\u00efve patients, and DOR of 16.7 months and PFS of 7.4 months in previously treated patients. Notably, vebreltinib\u2019s efficacy is not affected by co-occurring MET amplification, showing high ORR even in patients without MET amplification.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based…<\/p>\n","protected":false},"author":1,"featured_media":31786,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1927,3997],"class_list":["post-31783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-apollomics","tag-launxp-biomedical"],"yoast_head":"\nApollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31783\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31783\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-31T03:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T03:39:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3102-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment\",\"datePublished\":\"2025-03-31T03:30:00+00:00\",\"dateModified\":\"2025-04-15T03:39:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783\"},\"wordCount\":271,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3102-png.webp\",\"keywords\":[\"Apollomics\",\"LaunXP Biomedical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31783#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31783\",\"name\":\"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3102-png.webp\",\"datePublished\":\"2025-03-31T03:30:00+00:00\",\"dateModified\":\"2025-04-15T03:39:12+00:00\",\"description\":\"Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31783\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3102-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3102-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31783#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment - Insight, China's Pharmaceutical Industry","description":"Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31783","og_locale":"en_US","og_type":"article","og_title":"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment","og_description":"Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.","og_url":"https:\/\/flcube.com\/?p=31783","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-31T03:30:00+00:00","article_modified_time":"2025-04-15T03:39:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3102-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31783#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31783"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment","datePublished":"2025-03-31T03:30:00+00:00","dateModified":"2025-04-15T03:39:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31783"},"wordCount":271,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31783#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3102-png.webp","keywords":["Apollomics","LaunXP Biomedical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31783#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31783","url":"https:\/\/flcube.com\/?p=31783","name":"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31783#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31783#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3102-png.webp","datePublished":"2025-03-31T03:30:00+00:00","dateModified":"2025-04-15T03:39:12+00:00","description":"Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31783#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31783"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31783#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3102-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3102-png.webp","width":1080,"height":608,"caption":"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31783#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3102-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31783"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31783\/revisions"}],"predecessor-version":[{"id":31787,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31783\/revisions\/31787"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31786"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}